by mfantozzi | Oct 15, 2021 | 2021, Press Releases, Scientific
Philogen announces that Philochem’s European Patent 3083957 relating to important features of proprietary DNA-encoded chemical libraries (“ESAC 2+1” technology) was upheld after Oral Proceedings in front of the Opposition Division at the European Patent Office. Read...by mfantozzi | Oct 13, 2021 | 2021, Press Releases, Scientific
Philogen S.p.A. announces an update on the worldwide license agreement with Pfizer to develop Dekavil, a novel investigational therapy for the treatment of autoimmune diseases. Read moreby mfantozzi | Sep 29, 2021 | 2021, Press Releases, Scientific
Philogen provides corporate updateby mfantozzi | Aug 27, 2021 | 2021, Press Releases, Scientific
We are pleased to announce that Philogen co-founder and CEO/CSO, Prof. Dario Neri is giving two lectures on September 1st, 2021: At the virtual International Symposium on Medicinal Chemistry (EFMC-ISMC 2021) Prof. Neri is giving a presentation at 15:35 (CEST) with the...by last | Aug 23, 2021 | 2021, Press Releases, Scientific
Philochem, a wholly owned subsidiary of Philogen S.p.A., InterX, Inc and Scripps Research announce a research collaboration to develop a best-in-class tumor targeting agent for metastatic prostate cancer. Read Moreby mfantozzi | Jul 2, 2021 | 2021, Press Releases, Scientific
Fibromun shows activity in pretreated glioma and sarcoma patients; OncoFAP targets tumor lesions in cancer patients; a new product partnered with AbbVie entered clinical studies Read more
Recent Comments